Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

Crunchbase Data: Global Startup Investment Hit Record $510B In H1 2026 As AI Boom Accelerates Funding And Exits

View original at news.crunchbase.com
Crunchbase News - Funding Ma Title: Crunchbase Data: Global Startup Investment Hit Record $510B In H1 2026 As AI Boom Accelerates Funding And Exits Date: 2026-07-02 11:00 Source: https://news.crunchbase.com/venture/global-startup-exits-ipo-ma-soar-ai-q2-h1-2026/ <p>Global venture funding reached a record $510 billion i…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Global venture funding reached a record $510 billion in the first half of 2026, surpassing the $440 billion invested in all of 2025 and setting a new high for startup investment in any half-year period on record.

    60% confidence

  • Q2 2026 exit amounts were the highest on record for venture-backed companies for both acquisitions and IPOs.

    60% confidence

  • Q2 2026 was the second-largest quarter on record for global venture investment, following the largest quarter on record in Q1 2026.

    60% confidence

  • OpenAI and Anthropic together attracted more than 40% of all venture funding during H1 2026, highlighting how centered the current market is on the biggest frontier AI players.

    60% confidence

  • More than 70% of global startup capital in Q2 2026 was invested in AI-focused companies, up from just under 50% a year earlier.

    60% confidence

Data points we hold from this source

Anthropic · funding raised65 USD
SpaceX · ipo proceeds75 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com